Andrew J. Muratore is Vice President and Chief Counsel, Strategic Partnership & Investments at Pfizer. Since joining Pfizer in 2008, Andrew has served as lead counsel to Pfizer Ventures and in that role provides transactional and business counselling in support of all aspects of Pfizer’s equity investing activity. Andrew has advised on the evaluation, structuring and execution of numerous public and private equity and debt financings and exit transactions. Andrew also advises the Pfizer Ventures team on securities, compliance, governance and general legal matters. Andrew is Pfizer Venture’s designated board observer to Prescriber Point, Inc. and has previously served on the boards of Neuronetics (NASDAQ: STIM) and G-Con Manufacturing.

In addition to support for Pfizer Ventures, Andrew has led many of Pfizer's most significant M&A efforts, including the acquisitions of Global Blood Therapeutics, Biohaven, Trillium, Medivation and Hospira, as well as the combination of Pfizer’s consumer healthcare business with GSK’s to create Haleon PLC, the initial public offering and subsequent split-off of Zoetis, Pfizer’s Animal Health business, and the sale of Capsugel to KKR.

Andrew joined Pfizer in 2008 from Covington & Burling LLP. He holds a J.D. from New York University (magna cum laude, Order of the Coif) and a B.A. from Colgate University (magna cum laude). Andrew is admitted to practice law in New York.

Email: [email protected]